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Abstract
BACKGROUND: Radiation-induced mucositis is one of the limiting factors during radiotherapy, disturbing the 
quality of life and in some cases leading to discontinuation of therapy. Intensity-modulated radiation therapy (IMRT) 
with simultaneous integrated boost (SIB) represents advanced form of radiotherapy technique in treatment of 
oropharyngeal carcinoma enabling precision cancer targeting with reducing dose to healthy normal tissues.
AIM: The aim of this study was to present maximum grade and duration of a maximum grade of radiation-induced 
acute mucositis, influence of total volume of oral mucosa, and volumes of oral mucosa which are encompassed 
by radiation volume of 54 Gy and 66 Gy on the expression of grade of acute mucositis and influence of primary 
origin of tumor on encompassing with radiation volumes in patients treated with moderate acceleration of IMRT-SIB 
concomitant weekly cycle of chemotherapy with cisplatin.
MATERIALS AND METHODS: Planned research included 30 patients with oropharyngeal cancer who received their 
treatment at the University Clinic of Radiotherapy and Oncology in Skopje with moderate acceleration of IMRT-SIB 
and weekly concomitant cisplatin. Assessment of radiation-induced acute mucositis was performed according to the 
acute radiation morbidity scoring criteria of the Radiation Therapy Oncology Group.
RESULTS: Maximum grade of acute reaction was confluent mucositis with strong pain and was manifested in 
27 patients (90%) with maximum time of duration of 28 days (range 7–28) and median duration of 18 days (range 
7–28). Patients, in whom the primary origin of tumor was base of the tongue, a statistically significant difference 
(p = 0.04) was found for volume of oral mucosa encompassed with PTV66, compared to other localizations of 
primary oropharyngeal origin. Statistically non-significant difference was found between volume of total oral mucosa 
and volumes of oral mucosa which are encompassed with radiation volume of 54 Gy and 66 Gy and expression of 
grade of acute mucositis in the 5th and 6th weeks of radiotherapy.
CONCLUSION: According to these results, recommendations are delineation of oral mucosa as critical structure and 
implementation of IMRT-SIB to achieve reduction of grade of acute mucositis.
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Introduction
Oropharyngeal squamous cell carcinoma 
belongs to group of rare solid head-and-neck tumors with 
global annual incidence of 0.9/100,000. In year 2018, there 
were registered 92,887 new cases and 51,005 deaths from 
this disease [1]. The most common presentation is tonsil, 
followed by base of tongue, soft palate, and posterior 
pharyngeal wall. Definitive radiotherapy combined with 
concomitant chemotherapy is the treatment of choice 
for locally advanced oropharyngeal carcinoma with 
significant better overall survival and time to progression 
compared to other treatment modalities [2], [3].
Definitive radiotherapy, as a treatment of 
choice for planocellular oropharyngeal carcinoma, 
causes acute and late radiation-induced adverse 
events. Concomitant chemotherapy with radiotherapy 
other than increasing locoregional disease control 
and survival, it also increases acute toxicity during 
therapy [4,] [5], [6]. Radiation-induced mucositis 
represents one of the limiting factors during realization 
of radiotherapy causing pain, difficulty swallowing and 
chewing, and decreasing the quality of life. Mucositis 
is reaction of mucosa caused by radiation followed by 
inflammation, ulceration, and healing. When confluent 
mucositis reaches the maximum, further increasing of 
dose and cell death will not cause increasing of grade 
of mucositis. It will only affect duration of mucositis and 
recovering process [7]. Intensity and duration of acute 
mucositis depend on tumor localization, tumor size, daily 
dose in fraction, duration of radiotherapy, and technique 
of radiotherapy. It also depends on mucosal surface 
covered by radiаtion and patient’s general condition.
Intensity-modulated radiation therapy (IMRT) 
with simultaneous integrated boost (SIB) represents an 
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advanced form of radiotherapy technique in the treatment 
of oropharyngeal carcinoma, enabling precision cancer 
targeting with reducing dose to healthy normal tissues [8]. 
Simultaneous delivery of different doses in different 
regions in the same fraction with IMRT-SIB allows higher 
homogeneity, conformity, and consistency of dose in 
tumor volume [9], [10]. Advantage of this technique is 
delivering lower dose to critical structures and capability 
of treatment acceleration which will result in reducing 
of treatment time and escalation of dose in tumor 
volume [11]. IMRT-SIB achieves delivering higher dose in 
tumor and causes mucositis but lowers dose in fraction to 
other mucosal regions enabling minimization of mucosal 
radiation toxicity. Lower dose in fraction in elective regions 
reduces radiodermatitis in irradiated region. Otherwise, 
with increasing conformity in high- dose regions, we 
can reduce long-term dysphagia and tracheal toxicity. 
All of this indicate that beside certain regions which are 
irradiated with high dose, simultaneous irradiated regions 
with lower dose in IMRT-SIB technique will reduce acute 
and late radiation-induced toxicities [10], [12].
Aim
The aim of this study is to present maximum 
grade and duration of a maximum grade of radiation-
induced acute mucositis, influence of total volume of 
oral mucosa, and volumes of oral mucosa which are 
encompassed with radiation volume of 54 Gy and 
66 Gy on expression of grade of acute mucositis and 
influence of primary origin of tumor on encompassing 
with radiation volumes in patients treated with moderate 
acceleration with IMRT-SIB and concomitant weekly 
cycle of chemotherapy with cisplatin.
Materials and Methods
Patients characteristics
This planned non-randomized research 
represents study on 30 patients with advanced 
oropharyngeal carcinoma treated at University Clinic 
of Radiotherapy and Oncology – Skopje, Republic 
of Macedonia, from September 2017 to September 
2019 with moderate acceleration with IMRT-SIB and 
concomitant weekly cycle of chemotherapy with cisplatin. 
Detailed patients characteristics are shown in Table 1 
with stratification by gender, age, localization of primary 
tumor, and stage. Patients are staged according to eighth 
edition American Joint Committee on Cancer [13].
Treatment
Patient immobilization for computed 
tomography (CT) simulation is in supine position with 
hyperextended neck. We use thermoplastic mask 
for immobilization of head, neck, and shoulder to 
reproduce always the same position during treatment. 
CT simulation for treatment planning is performed on 
2.5 mm transverse cross-sections without intravenous 
contrast. Delineation of targeted volumes was according 
to protocol study Radiation Therapy Oncology Group 
(RTOG) H-0022 [14].
Gross tumor volume-P66 (GTV-P66) is the 
primary tumor and gross tumor volume-N66 (GTV-N66) 
represents the metastatic lymph nodes determined with 
endoscopy, CT, and magnetic resonance imaging. GTV 
66 is obtained with integration of these two volumes which 
included primary disease. Analogous to the previous 
volumes is added CTV-P66 and CTV-N66 (clinical target 
volume – CTV66) which are obtained by expanding GTV 
for 0.5 mm. After this, we delineated elective regions with 
lymph nodes in the neck (CTV-N54) where there are 
included metastatic lymph nodes (GTV-N66) with margin 
expansion from 1 cm to 2 cm and CTV-P54 with margin 
expansion from 1 to 2 cm from GTV-P66. With integration 
of CTV-N54 and CTV-P54, clinical target volume (CTV54) 
is created. Planning target volume – PTV66 and PTV54 
are represented with geometrical margin of 5 mm around 
CTV-N54 and CTV-P54 (Figure 1).
Table 1: Patients characteristics (n=30)
Characteristics Number of patients (%)
Gander
Male 26 (87)
Female 4 (13)
Age, years
Middle 59.4
Range 30–70
Localization of primary tumor
Tonsils 17 (65)
Base of tongue 8 (15)
Posterior wall of hypopharynx 3 (12)
Soft palate 2 (8)
Т (Primary tumor)
Т3 7 (23)
Т4a1 6 (54)
T4b 7 (23)
N (regional lymph nodes)
N0 3 (10)
N1 6 (20)
N2b 7 (23)
N2c 5 (17)
N3b 9 ( 30)
Stage
III 4 (13)
IVA 14 (47)
IVB 12 (40)
Figure 1: Delineated and integrated CTN-N54 and CTV-P54
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As normal structure of interest that was 
delineated in every patient was oral mucosa. Main 
interests of this research were volume of oral mucosa 
encompassed with 54 Gy which is cross-section 
between the total oral mucosa and PTV54 and oral 
mucosa encompassed with 66 Gy which is cross-section 
between the total oral mucosa and PTV66 consequently 
obtaining a volume of the total oral mucosa which is 
irradiated with 54 Gy or 66 Gy (Figure 2).
Figure 2: Three-dimensional view after delineated and integrated 
planning target volumes and organs at risk
IMRT-SIB technique used in this study is 
based on the RTOG H-0022 study [14]. Patients were 
irradiated once daily, 5 days in the week with total tumor 
dose till 66 Gy in 30 fractions. GTV as high-risk area 
was irradiated with dose 2.2 Gy in fraction and in the 
same time in same fraction 1.8 Gy was given to elective 
irradiated area CTV54 (Figure 3) [15].
Figure 3: Planning and scheduling the fields using IMRT technique
Planning and scheduling the fields with this 
technique allows more sparing of healthy tissue 
and consecutively high quality of life in patients with 
oropharyngeal cancer [10], [11].
All of the patients, starting from the 1st week 
then once weekly, received concurrent chemotherapy, 
during radiotherapy, cisplatin 30 mg/m², total of 6 times 
during the entire treatment. The day when cisplatin 
is administered, radiotherapy fraction is realized in 
1–3 h after chemotherapy. A total number of 6 cycles 
of weekly concurrent cisplatin were administrated in 
15 patients (50%), 5 cycles in 8 patients (27%), and 
in the remaining number of patients (23%), <5 cycles 
were administered. Mean total dose of administered 
concurrent cisplatin in all patients was 247 mg/m².
Assessment of acute mucositis
All patients were monitored once weekly 
in the period of 6 weeks during the radiation therapy 
in combination with concomitant chemotherapy. An 
assessment of radiation-induced acute mucositis 
was performed according to acute radiation morbidity 
scoring criteria of the RTOG with quantum descriptive 
scoring system from 0 to 4 (Table 2) [16].
Table 2: Grade of acute mucosal reaction according to quantum 
descriptive scoring system from 0 to 4 of RTOG
0 1 2 3 4
Without 
changes
Erythema/
weak pain
Punctiform mucositis/
middle pain
Confluent mucositis/
strong pain
Necrosis, ulceration, 
hemorrhagia
RTOG: Radiation Therapy Oncology Group.
Results
Characteristics of radiation-induced mucositis 
monitored during 6 weeks are presented in Table 3. 
Maximum grade of acute mucositis reaction was 
Grade 3 and was manifested in 27 patients (90%). 
Maximum time of duration of confluent mucositis 
was 28 days (range 7–28) and median duration of 
Grade 3 mucositis was 18 days (range 7–28).
Table 3: Characteristics of acute mucosal reactions on total oral
Characteristics Number of patients (%)
Maximum grade of acute reaction
Grade 2 3 (10)
Grade 3 27 (90)
Time to occurrence Grade 2 reaction/days
Average 22.6
Range 7–35
Duration of Grade 2 mucositis/days
Average 12.3
Range 7–35
Time to occurrence Grade 3 reaction/days
Average 27.5
Range 21–35
Duration of Grade 3 mucositis/days
Average 14.2
Range 7–28
The statistical methods used in this research 
were t-test and ANOVA.
Table 4 contains statistically obtained results 
information from comparing between volume of total 
oral mucosa, volume of oral mucosa encompassed with 
dose of 54 Gy, and volume of oral mucosa encompassed 
with 66 Gy with expression of acute mucositis Grade 2 
and 3 in the 5th week of radiotherapy.
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Results from comparison between investigated 
volumes of oral mucosa and expression of grade of 
acute mucositis in the 5th week were statistically non-
significant (p > 0.05).
Table 5 contains statistically obtained results 
information from comparing volume of total oral mucosa, 
volume of oral mucosa encompassed with dose of 54 Gy, 
and volume of oral mucosa encompassed with dose of 
66 Gy with Grade 2 mucositis (punctiform mucositis) and 
Grade 3 mucositis (confluent mucositis) in the 6th week 
of radiotherapy. There was statistically non-significant 
difference (p > 0.05) between volumes of oral mucosa 
and expression of degree of radiation-induced mucositis.
Table 5: Comparison between volume of oral mucosa with 
Grade 2 versus Grade 3 radiation-induced mucositis in the 
6th week of radiotherapy
Volume of oral mucosa (cm3) ± SD Degree of radiation-induced 
mucositis
p value
Grade 2
Number of 
patients = 11
Grade 3
Number of 
patients = 19
Total volume of oral mucosa 131.69 ± 27.30 122.00 ± 21.17 0.286
Volume of oral mucosa encompass 
with dose of 54 Gy
76.47 ± 33.61 85.81 ± 26.48 0.406
Volume of oral mucosa encompass 
with dose of 66 Gy
50.23 ± 29.97 67.05 ± 27.18 0.126
SD: Standard deviation.
Table 6 shows statistically obtained results 
information from comparing volume of total oral mucosa, 
volumes of oral mucosa encompassed with dose of 
54 Gy and 66 Gy with localization of primary origin of 
cancer or oropharyngeal cancer originating from the 
base of the tongue versus the cancers originating from 
the tonsillar region, soft palate, and pharyngeal wall. In 
patients, whose oropharyngeal cancer originates from 
base of tongue, a statistically significant difference was 
obtained (p = 0.040) on the volume of the oral mucosa 
covered by PTV66 in relation to other localizations 
(cancers originating from tonsils, soft palate, and 
pharyngeal wall).
Discussion
The main goal in radiotherapy is better targeting 
on tumor cells with minimal damage on surrounding 
healthy tissues which are a limiting factor in determining 
the prescribed dose of radiotherapy. Radiation-induced 
mucositis is one of the limiting factors during radiotherapy, 
disturbing the quality of life and in some cases leading to 
discontinuation of therapy. Which grade of acute mucositis 
will appear during radiotherapy depends on multiple 
factors such as dose in fraction, added concomitant 
chemotherapy, size of the tumor, and technique of 
radiotherapy. They also include the factors investigated 
in this research: Tumor localization and volume 
encompassed with planning targeted volume. Incidence 
of acute confluent mucositis with strong pain was present 
in 90% of the patients. Comparison between volumes of 
oral mucosa with expression of grade of acute mucositis in 
the past 2 weeks in radiotherapy showed statistically non-
significant difference. Results from this research showed 
that encompassed volume of total mucosa with planning 
target volume of 66 Gy is bigger when localization of the 
primary tumor is base of the tongue compared to other 
localization of oropharyngeal cancers.
Conclusion
According to the summarizing results obtained 
from this research, we can recommend delineating 
of oral mucosa during planning radiotherapy as a 
standard routine procedure and application of new 
modern radiotherapy techniques with better conformity 
and homogeneity of the dose, like IMRT-SIB to reduce 
side effects which significantly affect the quality of life 
during treatment.
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